Correspondence 0001654954-23-005113 from ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682) (NDRA)
ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682)
Date: April 24, 2023 · CIK: 0001681682 · Accession: 0001654954-23-005113
AI Filing Summary & Sentiment
File numbers found in text: 333-271003
Letter
Re: Acceleration Request for ENDRA Life Sciences Inc. Registration Statement on Form S-1 (File No. 333-271003)
endra_corresp
April 24, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street N.E.
Washington, D.C. 20549
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, ENDRA Life Sciences Inc. (the “Company”) hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 p.m., Washington, D.C. time, on April 26, 2023 or as soon thereafter as is practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff.
It would be appreciated if, as soon as the Registration Statement is declared effective, you would so inform Coleman Wombwell of K&L Gates LLP, our counsel, at (704) 331-7551. We appreciate your assistance in this matter.
Very
truly yours,
ENDRA Life Sciences Inc.
Show Raw Text
CORRESP 1 filename1.htm endra_corresp April 24, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Acceleration Request for ENDRA Life Sciences Inc. Registration Statement on Form S-1 (File No. 333-271003) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, ENDRA Life Sciences Inc. (the “Company”) hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 p.m., Washington, D.C. time, on April 26, 2023 or as soon thereafter as is practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff. It would be appreciated if, as soon as the Registration Statement is declared effective, you would so inform Coleman Wombwell of K&L Gates LLP, our counsel, at (704) 331-7551. We appreciate your assistance in this matter. Very truly yours, ENDRA Life Sciences Inc. By: /s/ Francois Michelon Name: Francois Michelon Title: President and Chief Executive Officer